Follow Health Care Reform Insider on Twitter
You are here:  Home  >  Emerging Healthcare Models  >  Current Article

Merck’s diabetes blockbuster Januvia boards pay-for-performance train with Aetna deal

October 12, 2016 

Add Merck to the list of companies participating in pay-for-performance deals. Facing stepped-up competition in diabetes, the pharma signed a value-based contract with leading insurer Aetna on its blockbuster meds Januvia and Janumet.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>